R1	Has_value Arg1:T3 Arg2:T4	
R2	Subsumes Arg1:T1 Arg2:T3	
R3	Has_multiplier Arg1:T2 Arg2:T1	
R4	Has_temporal Arg1:T2 Arg2:T7	
R5	Has_value Arg1:T8 Arg2:T9	
R6	Has_qualifier Arg1:T9 Arg2:T10	
R7	AND Arg1:T8 Arg2:T11	
R8	Has_mood Arg1:T15 Arg2:T14	
R9	Has_temporal Arg1:T15 Arg2:T16	
R10	Has_index Arg1:T21 Arg2:T23	
R11	multi Arg1:T23 Arg2:T22	
R12	Has_multiplier Arg1:T19 Arg2:T20	
R13	Has_temporal Arg1:T19 Arg2:T21	
R14	Has_mood Arg1:T19 Arg2:T18	
R15	Subsumes Arg1:T1 Arg2:T5	
R16	AND Arg1:T8 Arg2:T12	
T1	Multiplier 6 15	half-dose
T2	Drug 16 26	ticagrelor
T3	Measurement 28 40	loading dose
T4	Value 41 45	90mg
T5	Multiplier 56 67	45mg bidpo.
T7	Temporal 69 89	treatment for 3 days
T8	Measurement 95 115	platelet aggregation
T9	Value 131 140	inhibited
T10	Qualifier 119 130	effectively
T11	Procedure 144 175	light transmission aggregometry
T12	Procedure 187 205	thromboela-stogram
T14	Mood 208 226	planned to undergo
T15	Procedure 227 230	PCI
T16	Temporal 231 239	recently
T18	Mood 241 251	planned to
T19	Procedure 252 256	DAPT
T20	Multiplier 257 267	for 1 year
T21	Temporal 268 277	after PCI
T22	Procedure 274 277	PCI
T23	Reference_point 274 277	PCI
